DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07546357

Not yet recruitingPhase NA

AIManage Using an AI-driven CDS and Chatbot

AIManage: Using an AI-driven CDS and Chatbot for the Management of Patients on Incretin Mimetic Medications

Lead sponsor

NYU Langone Health

Asset

GLP-1 / incretin class catch-all

Listed sites

1

Recruiting sites

—

Enrollment

16

estimated

Study population

Diabetes (other / unspecified), Obesity / overweight

Key I/E criterion

—

Primary endpoints

•Percentage of Patients who Complete Qualitative Measure - Perceived Usefulness•Percentage of Patients who Complete Qualitative Measure - Perceived Usability•Percentage of Patients who Complete Qualitative Measure - Perceived Use

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07546357
Org study ID25-00594
Secondary ID1R01DK144008

Timeline

Milestones

Study first posted2026-04-22actual
Last update posted2026-04-22actual
Study start2026-06-01estimated
Primary completion2028-03-30estimated
Study completion2029-03-30estimated

Assets

Investigational agents

GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Diabetes (other / unspecified)Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

Provider Eligibility Criteria (Phase 1)

•Primary or bariatric care provider (MD/DO, NP) practicing at the participating NYULH clinics,
•Provide care to at least 5 patients prescribed an IMM.

Patient Eligibility Criteria (Phase 1)

•(Phase 1) Currently taking an IMM or have taken an IMM in the past 6 months;
•Fluency in English or Spanish;
•Be willing to send/receive text messages; and
•Be > 18 years of age.

Exclusion criteria

Provider Exclusion Criteria (Phase 1) • Refuse to participate

Patient Exclusion Criteria (Phase 1)

• Refuse or are unable to provide informed consent;

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Patient-reported / QoL

4 endpoints
Primary/protocol endpoint

Percentage of Patients who Complete Qualitative Measure - Perceived Usefulness

Time frame:Day 1 (60 minutes)

threshold achievement, descriptive

Primary/protocol endpoint

Percentage of Patients who Complete Qualitative Measure - Perceived Usability

Time frame:Day 1 (60 minutes)

descriptive

Primary/protocol endpoint/low confidence

Percentage of Patients who Complete Qualitative Measure - Perceived Use Challenges

Time frame:Day 1 (60 minutes)

descriptive

Primary/protocol endpoint

Percentage of Patients who Complete Qualitative Measure - Perceived Value

Time frame:Day 1 (60 minutes)

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.